*Huaxun stock may be suspended

Survival Rules for Turbulent Times: A Compilation of the 20 Most Unmissable Core Insights from the 2026 Tsinghua PBCSF Forum

A dialogue between Zhu Min, former Deputy Governor of the People's Bank of China and former Vice Managing Director of the International Monetary Fund; Michael Spence, 2001 Nobel Prize winner in Economics and Philip H. Knight Professor Emeritus of Management at Stanford Graduate School of Business; and Masaaki Shirakawa, former Governor of the Bank of Japan, at the 2026 Tsinghua PBCSF Global Finance Forum.

Ant International Raises About US$1.2 Billion in Series A Financing

Ant International（蚂蚁国际）has completed a Series A equity financing round of approximately US$1.2 billion to support its global expansion and the development of payment and financial-technology services for businesses.

Insilico Medicine (英矽智能) Signs Strategic Drug Discovery Partnership with Takeda (武田制药), Deal Worth Up to US$600 Million

Chinese AI drug discovery company Insilico Medicine (英矽智能) has signed a global strategic collaboration with Japanese pharmaceutical company Takeda (武田制药), with the total potential deal value reaching up to US$600 million. Announced in early July, the agreement marks another milestone in the international commercialization of China's AI-powered drug discovery technologies through collaboration with a leading multinational pharmaceutical company.

Drug Farm Raises $55 Million in First Closing of Series D Financing

According to EO (亿欧), Drug Farm (药物牧场) announced on July 13 that it had raised $55 million in the first closing of its Series D financing round.

China's First Outbound Investment Regulation Takes Effect, Creating a Unified Rulebook for 50,000 Overseas Enterprises

China's State Council regulation on outbound investment came into force on July 1, 2026, establishing for the first time a single administrative-rule framework to govern the more than 50,000 Chinese enterprises that operate outside the country.